An eminent Alzheimer’s disease (AD) scientist, Michel Goedert, and an early career genomic engineering investigator, Patrick Hsu, are inaugural winners of the Rainwater Prize Program that acknowledges leading work in brain research. Such work includes groundbreaking efforts to advance new treatments for neurodegenerative disorders, including Alzheimer’s, that are associated with…
CareBand’s tracking bracelet, which pairs GPS technology to track movement and activity in real time, has been granted the National Institutes of Health (NIH) Phase 1 Small Business Innovation Research (SBIR) Award to test whether it may help detect and predict agitation in patients with Alzheimer’s…
Biogen is planning to seek approval for aducanumab, an injectable treatment under investigation for patients with early Alzheimer’s disease, following a new analysis of Phase 3 studies supporting meaningful benefits for patients’ cognition and daily life abilities. After meeting with the U.S. Food and Drug Administration…
Targeting a single enzyme called PI3K-delta prevented neuroinflammation, reduced the accumulation of toxic amyloid-beta plaques in the brain, and prevented memory deficits in a mouse model of Alzheimer’s disease, a new study shows. This approach, which also increased the animals’ life span, may represent a potential new strategy to…
The writing style of a woman’s diary entries over 31 years has given researchers a glimpse into the progression of her cognitive decline from Alzheimer’s disease, revealing a relationship between language use and the transition from healthy to severe dementia. University of Toronto (UT) researchers specializing in language…
Oral treatment over one year with an approved blood thinner called dabigatran prevented memory loss, preserved blood circulation in the brain and reduced the amount of senile plaques in a mouse model of Alzheimer’s disease. The study with that finding, “Long-Term Dabigatran Treatment Delays Alzheimer’s Disease Pathogenesis…
Anavex Life Sciences has launched an extension study — called ATTENTION-AD — to investigate the long-term safety and efficacy of Anavex 2-73 in delaying cognitive decline in people with early Alzheimer’s disease. Eligible patients are those now taking part in the company’s 48-week ANAVEX2-73-AD-004 study underway in…
Treatment with Nuplazid (pimavanserin) significantly delays time to a psychosis relapse in people with dementia-related disorders such as Alzheimer’s and Parkinson’s diseases, according to results from the ongoing Phase 3 HARMONY study. Evaluation by an independent data monitoring committee recommended an early stop to this trial based on the…
Athira Pharma has completed the Phase 1 trial testing NDX-1017, its lead therapeutic candidate for Alzheimer’s disease, and will present the results at the 12th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference in December. Preliminary results showed the therapy, which has the potential to be regenerative and…
To advance the pipeline for innovative therapeutics in Alzheimer’s (AD), the National Institute on Aging (NIA) will invest an expected $73 million over five years in two new translational research centers. The centers will be funded through the NIA’s Alzheimer Centers for…
Get regular updates to your inbox.